- Team I
- Our projects aim to understand the pathophysiological role of key cell effectors of the immune system (Dendritic cells, B cells, Neutrophils and regulatory T cells) and chemokines in immunological disorders, viral diseases and cancers associated with immune diseases (eg WHIM syndromes and myelodysplastic syndromes, Idiopathic CD4 T Lymphopenia) and the production of autoantibodies characteristic of autoimmune diseases (eg lupus erythematosus)
- Team II
- Projects involving the analysis of inflammatory diseases induced by adjuvants or chemical or drug agents have focused on the roles of the transcription factor Nrf2, the neutrophil, Dendritic cells and T-cell responses (Team II)
- Team III
- Regarding the pathogenic mechanisms of liver inflammation due to excessive alcohol consumption and metabolic syndrome, our projects are more specifically targeting the role of gut microbiota and liver resident macrophages (eg Kupffer cells)
Original therapeutic strategies are being developed by the three teams in the LabEx LERMIT « Laboratory of Excellence in Research on Medication and Innovative Therapeutics » with the aim of identifying antagonists of the chemokine CXCL12 and its receptors, immunomodulator liposomes in the context of hepatic inflammation, and therapeutic targets for the control of autoimmune B cells in the context of Lupus erythematosus, and of analyzing resistance mechanisms to immunotherapies in autoimmune and inflammatory syndromes (eg rheumatoid arthritis). The UMR-996 is also a partner of an EQUIPEX project dedicated to the innovative « mass cytometry » technology or CyTOFTM.